$9.91
2.59% yesterday
Nasdaq, Aug 12, 10:03 pm CET
ISIN
US45257U1088
Symbol
IMNM

Immunome Inc Stock price

$9.91
+1.40 16.45% 1M
-0.49 4.71% 6M
-0.71 6.69% YTD
-2.73 21.60% 1Y
+4.55 84.89% 3Y
-3.54 26.32% 5Y
-3.54 26.32% 10Y
-3.54 26.32% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.25 2.59%
ISIN
US45257U1088
Symbol
IMNM
Industry

Key metrics

Basic
Market capitalization
$840.9m
Enterprise Value
$523.5m
Net debt
positive
Cash
$317.3m
Shares outstanding
87.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
76.9 | 171.4
EV/Sales
47.9 | 106.7
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
75.4%
Return on Equity
-161.7%
ROCE
-57.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.9m | $4.9m
EBITDA
$-175.1m | $-198.9m
EBIT
$-177.7m | $-200.2m
Net Income
$-205.1m | $-196.3m
Free Cash Flow
$-178.9m
Growth (TTM | estimate)
Revenue
-13.8% | -45.7%
EBITDA
-297.3% | -31.4%
EBIT
-298.6% | -30.5%
Net Income
11.6% | 33.0%
Free Cash Flow
-121.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,600.6% | -4,054.2%
EBIT
-1,625.0%
Net
-1,875.2% | -4,000.5%
Free Cash Flow
-1,635.3%
More
EPS
$-2.6
FCF per Share
$-2.1
Short interest
17.0%
Employees
118
Rev per Employee
$80.0k
Show more

Is Immunome Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Immunome Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Immunome Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Immunome Inc forecast:

Buy
93%
Hold
7%

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
11 11
14% 14%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 38 38
64% 64%
344%
- Research and Development Expense 151 151
340% 340%
1,381%
-175 -175
297% 297%
-1,600%
- Depreciation and Amortization 2.67 2.67
413% 413%
24%
EBIT (Operating Income) EBIT -178 -178
299% 299%
-1,625%
Net Profit -205 -205
12% 12%
-1,875%

In millions USD.

Don't miss a Thing! We will send you all news about Immunome Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunome Inc Stock News

Positive
Seeking Alpha
about 20 hours ago
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potentially enabling accelerated approval if phase 3 results are positive. Cash reserves of $143.9M and marketable securities of $124.2M provide runway into 2027, despite a high annualized cash burn.
Positive
The Motley Fool
6 days ago
Immunome (IMNM -3.59%), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantial revenue beat, with $4.0 million in GAAP revenue topping analyst forecasts by a wide margin, plus a narrower-than-expected GAAP loss per share.
Neutral
Business Wire
6 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended June 30, 2025 and provided a business update. “Immunome made substantial progress in the second quarter of 2025, underscored by the continued advancement of our clinical p...
More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office United States
CEO Clay Siegall
Employees 118
Founded 2006
Website immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today